Inferior Vena Cava Filter Market

Executive Summary

Inferior Vena Cava Filter Market was valued at US $815.32 million in 2021 and is projected to grow at 8.25% CAGR over the forecast period to reach US $1,311.73 million by 2027. Inferior Vena Cava Filter Market represented US $119.51 million opportunity over 2019-2021 and estimated to create US $496.41 million opportunity in 2027 over 2021.

Inferior Vena Cava Filter from Consainsights analyses the Inferior Vena Cava Filter Market in the Life Sciences industry over the forecast period to 2027.

Inferior Vena Cava Filter research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Inferior Vena Cava Filter segmentation includes Application, Product Type, End-User and Geography.

Based on the Application, the Inferior Vena Cava Filter analysis covers Treatment of Venous Thromboembolism, Prevention of Pulmonary Embolism.

In Application segment, Treatment of Venous Thromboembolism segment has highest cagr growth of 7.30%.

Based on the Product Type, the Inferior Vena Cava Filter analysis covers Retrievable, Permanent.

In Product Type segment, Retrievable segment has highest cagr growth of 7.30%.

Based on the End-User, the Inferior Vena Cava Filter analysis covers Hospitals, Ambulatory Surgical Centers, Others.

In End-User segment, Hospitals segment has highest cagr growth of 7.30%.

Based on the region, the Inferior Vena Cava Filter analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include ALN, Argon Medical, B. Braun Melsungen AG, Becton, Dickinson and Company, Boston Scientific Corporation, Braile Biomedica, Cardinal Health, Cook Medical, Volcano Corporation and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Application

Introduction

In 2021, Treatment of Venous Thromboembolism segment has the highest revenue of US $540.24 million and is expected to grow at CAGR of 7.30% by 2027 Treatment of Venous Thromboembolism segment has highest cagr growth of 7.30%.

Treatment of Venous Thromboembolism

Treatment of Venous Thromboembolism segment was valued at US $461.05 million in 2019 and is projected to grow at 7.30% CAGR over the forecast period to reach US $869.17 million by 2027. Treatment of Venous Thromboembolism segment represented US $79.19 million opportunity over 2019-2021 and estimated to create US $328.93 million opportunity in 2027 over 2021.

Prevention of Pulmonary Embolism

Prevention of Pulmonary Embolism segment was valued at US $234.76 million in 2019 and is projected to grow at 7.30% CAGR over the forecast period to reach US $442.56 million by 2027. Prevention of Pulmonary Embolism segment represented US $40.32 million opportunity over 2019-2021 and estimated to create US $167.48 million opportunity in 2027 over 2021.

Product Type

Introduction

In 2021, Retrievable segment has the highest revenue of US $633.24 million and is expected to grow at CAGR of 7.30% by 2027 Retrievable segment has highest cagr growth of 7.30%.

Retrievable

Retrievable segment was valued at US $540.42 million in 2019 and is projected to grow at 7.30% CAGR over the forecast period to reach US $1,018.78 million by 2027. Retrievable segment represented US $92.82 million opportunity over 2019-2021 and estimated to create US $385.55 million opportunity in 2027 over 2021.

Permanent

Permanent segment was valued at US $155.39 million in 2019 and is projected to grow at 7.30% CAGR over the forecast period to reach US $292.95 million by 2027. Permanent segment represented US $26.69 million opportunity over 2019-2021 and estimated to create US $110.86 million opportunity in 2027 over 2021.

End-User

Introduction

In 2021, Hospitals segment has the highest revenue of US $356.92 million and is expected to grow at CAGR of 7.30% by 2027 Hospitals segment has highest cagr growth of 7.30%.

Hospitals

Hospitals segment was valued at US $304.60 million in 2019 and is projected to grow at 7.30% CAGR over the forecast period to reach US $574.23 million by 2027. Hospitals segment represented US $52.32 million opportunity over 2019-2021 and estimated to create US $217.31 million opportunity in 2027 over 2021.

Ambulatory Surgical Centers

Ambulatory Surgical Centers segment was valued at US $239.44 million in 2019 and is projected to grow at 7.30% CAGR over the forecast period to reach US $451.38 million by 2027. Ambulatory Surgical Centers segment represented US $41.13 million opportunity over 2019-2021 and estimated to create US $170.82 million opportunity in 2027 over 2021.

Others

Others segment was valued at US $151.77 million in 2019 and is projected to grow at 7.30% CAGR over the forecast period to reach US $286.12 million by 2027. Others segment represented US $26.07 million opportunity over 2019-2021 and estimated to create US $108.28 million opportunity in 2027 over 2021.